User profiles for Pablo Bascuñana

Pablo Bascuñana (ORCID 0000-0003-2186-8899)

Departamento de Medicina Nuclear, Hospital Clínico San Carlos, IdISSC, Madrid
Verified email at ucm.es
Cited by 666

The insulin‐like growth factor I receptor regulates glucose transport by astrocytes

…, A Perez‐Alvarez, L Genis, P Bascuñana… - Glia, 2016 - Wiley Online Library
Previous findings indicate that reducing brain insulin‐like growth factor I receptor (IGF‐IR)
activity promotes ample neuroprotection. We now examined a possible action of IGF‐IR on …

Isoflurane prevents acquired epilepsy in rat models of temporal lobe epilepsy

…, C Brandt, M Bankstahl, P Bascuñana… - Annals of …, 2016 - Wiley Online Library
Objective Acquired epilepsy is a devastating long‐term risk of various brain insults, including
trauma, stroke, infections, and status epilepticus (SE). There is no preventive treatment for …

Serial quantitative TSPO-targeted PET reveals peak microglial activation up to 2 weeks after an epileptogenic brain insult

M Brackhan, P Bascuñana, JM Postema… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Experimental and clinical evidence suggests that neuroinflammation, triggered by
epileptogenic insults, contributes to seizure development. We used translocator protein–targeted …

[HTML][HTML] Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis

P Bascuñana, L Möhle, M Brackhan, J Pahnke - Drugs in R&D, 2020 - Springer
Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its
properties in different pathways have raised interest in therapy research for other …

Blood–brain barrier leakage during early epileptogenesis is associated with rapid remodeling of the neurovascular unit

M Bankstahl, H Breuer, I Leiter, M Märkel, P Bascuñana… - Eneuro, 2018 - eneuro.org
Increased permeability of the blood–brain barrier (BBB) following cerebral injury results in
regional extravasation of plasma proteins and can critically contribute to the pathogenesis of …

[HTML][HTML] ABC transporter C1 prevents dimethyl fumarate from targeting Alzheimer's disease

L Möhle, K Stefan, P Bascuñana, M Brackhan… - Biology, 2023 - mdpi.com
Simple Summary Reusing drugs could potentially shorten the development time for the
effective treatment of dementia. Here, we tested a drug—dimethyl fumarate—for its efficacy in …

[HTML][HTML] Molecular imaging of the brain–heart axis provides insights into cardiac dysfunction after cerebral ischemia

N Hermanns, V Wroblewski, P Bascuñana… - Basic Research in …, 2022 - Springer
Ischemic stroke imparts elevated risk of heart failure though the underlying mechanisms
remain poorly described. We aimed to characterize the influence of cerebral ischemic injury on …

[HTML][HTML] Time-and sex-dependent effects of fingolimod treatment in a mouse model of alzheimer's disease

P Bascuñana, M Brackhan, L Möhle, J Wu, T Brüning… - Biomolecules, 2023 - mdpi.com
Alzheimer’s disease (AD) is the most common cause of dementia. Fingolimod has
previously shown beneficial effects in different animal models of AD. However, it has shown …

[HTML][HTML] Dimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice

L Möhle, M Brackhan, P Bascunana, J Pahnke - Brain Research, 2021 - Elsevier
Introduction Alzheimer’s disease (AD) is the leading cause of dementia and a major global
health issue. Currently, only limited treatment options are available to patients. One …

[HTML][HTML] Development of deep learning models for microglia analyses in brain tissue using DeePathology™ STUDIO

L Möhle, P Bascunana, M Brackhan… - Journal of neuroscience …, 2021 - Elsevier
Background Interest in artificial intelligence-driven analysis of medical images has seen a
steep increase in recent years. Thus, our paper aims to promote and facilitate the use of this …